NASD · Healthcare · Biotechnology · USA
Tango Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Tango Therapeutics develops targeted oncology medicines by identifying novel targets and designing small molecules tailored to cancer cells with specific genetic alterations. The company is advancing clinical development of two PRMT5 inhibitors: vopimetostat for non-CNS tumors both alone and paired with RAS inhibitors, and TNG456, a brain-penetrant variant for CNS cancers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Tango Therapeutics Inc stock.
Overvalued: intrinsic value $6.58 per share, market price $23.53, margin of safety -257.5% (as of 2026-10-19).
A 2.4x revenue multiple, discounted for its losses, values the shares at $6.58; the price of $23.53 is 257% above that value.
17 more funds hold it; the full list is part of the paid plan.
80 more in this industry show a wider margin of safety.
TNGX is overvalued (as of the 2026-10-19 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $6.58; the price of $23.53 is 257% above that value.
$6.58 per share (as of the 2026-10-19 close), against a market price of $23.53. That is a margin of safety of -257.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.